A Simple Method for the Routine Detection of Somatic Quantitative Genetic Alterations in Colorectal Cancer

Gastroenterology

Volumn 132, Issue 2, 2007, Pages 645-653

  Killian, Audrey ^a,b   Di Fiore, Frédéric ^a,b,c   Le Pessot, Florence ^b,c   Blanchard, France ^b,c   Lamy, Aude ^b,c   Raux, Grégory ^a,b   Flaman, Jean Michel ^a,b   Paillot, Bernard ^b,c   Michel, Pierre ^a,b,c   Sabourin, Jean Christophe ^a,b,c   Tuech, Jean Jacques ^b,c   Michot, Francis ^b,c   Kerckaert, Jean Pierre ^b,d   Sesboüé, Richard ^a,b   Frebourg, Thierry ^a,b  

^a UNIVERSITÉ DE ROUEN   (France)

^b North West Canceropole   (France)

^c ROUEN UNIVERSITY HOSPITAL   (France)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOTRANSFERASE;

ANALYTIC METHOD; ARTICLE; AURKA GENE; CANCER PATIENT; CHROMOSOME 17P; CHROMOSOME 18Q; CHROMOSOME 20Q; CHROMOSOME 8Q; COLORECTAL CANCER; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DCC GENE; EGFR GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE DELETION; GENE FREQUENCY; GENE LOCUS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MET GENE; ONCOGENE MYC; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PTK2 GENE; QUANTITATIVE ANALYSIS; QUANTITATIVE GENETICS; QUANTITATIVE MULTIPLEX POLYMERASE CHAIN REACTION OF SHORT FLUORESCENT FRAGMENTS; REAL TIME POLYMERASE CHAIN REACTION; TP53 GENE;

EID: 33847233287     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2006.12.006     Document Type: Article

References (32)

1. Westra J.L., Schaapveld M., Hollema H., de Boer J.P., Kraak M.M., de Jong D., ter Elst A., Mulder N.H., Buys C.H., Hofstra R.M., and Plukker J.T. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol 23 (2005) 5635-5643
2. Russo A., Bazan V., Iacopetta B., Kerr D., Soussi T., and Gebbia N. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 23 (2005) 7518-7528
3. Gryfe R., Kim H., Hsieh E.T., Aronson M.D., Holowaty E.J., Bull S.B., Redston M., and Gallinger S. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 342 (2000) 69-77
4. Ribic C.M., Sargent D.J., Moore M.J., Thibodeau S.N., French A.J., Goldberg R.M., Hamilton S.R., Laurent-Puig P., Gryfe R., Shepherd L.E., Tu D., Redston M., and Gallinger S. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349 (2003) 247-257
5. Lanza G., Matteuzzi M., Gafa R., Orvieto E., Maestri I., Santini A., and del Senno L. Chromosome 18q allelic loss and prognosis in stage II and III colon cancer. Int J Cancer 79 (1998) 390-395
6. Watanabe T., Wu T.T., Catalano P.J., Ueki T., Satriano R., Haller D.G., Benson III A.B., and Hamilton S.R. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 344 (2001) 1196-1206
7. Barratt P.L., Seymour M.T., Stenning S.P., Georgiades I., Walker C., Birbeck K., and Quirke P. DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet 360 (2002) 1381-1391
8. Diep C.B., Thorstensen L., Meling G.I., Skovlund E., Rognum T.O., and Lothe R.A. Genetic tumor markers with prognostic impact in Dukes' stages B and C colorectal cancer patients. J Clin Oncol 21 (2003) 820-829
9. Jen J., Kim H., Piantadosi S., Liu Z.F., Levitt R.C., Sistonen P., Kinzler K.W., Vogelstein B., and Hamilton S.R. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 331 (1994) 213-221
10. Popat S., and Houlston R.S. A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur J Cancer 41 (2005) 2060-2070
11. Ogunbiyi O.A., Goodfellow P.J., Herfarth K., Gagliardi G., Swanson P.E., Birnbaum E.H., Read T.E., Fleshman J.W., Kodner I.J., and Moley J.F. Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J Clin Oncol 16 (1998) 427-433
12. Font A., Abad A., Monzo M., Sanchez J.J., Guillot M., Manzano J.L., Pinol M., Ojanguren I., and Rosell R. Prognostic value of K-ras mutations and allelic imbalance on chromosome 18q in patients with resected colorectal cancer. Dis Colon Rectum 44 (2001) 549-557
13. Chang S.C., Lin J.K., Lin T.C., and Liang W.Y. Loss of heterozygosity: an independent prognostic factor of colorectal cancer. World J Gastroenterol 11 (2005) 778-784
14. Zhang H., Arbman G., and Sun X.F. Codon 201 polymorphism of DCC gene is a prognostic factor in patients with colorectal cancer. Cancer Detect Prev 27 (2003) 216-221
15. Aust D.E., Muders M., Kohler A., Schmidt M., Diebold J., Muller C., Lohrs U., Waldman F.M., and Baretton G.B. Prognostic relevance of 20q13 gains in sporadic colorectal cancers: a FISH analysis. Scand J Gastroenterol 39 (2004) 766-772
16. Moroni M., Veronese S., Benvenuti S., Marrapese G., Sartore-Bianchi A., Di Nicolantonio F., Gambacorta M., Siena S., and Bardelli A. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6 (2005) 279-286
17. Lievre A., Bachet J.B., Le Corre D., Boige V., Landi B., Emile J.F., Cote J.F., Tomasic G., Penna C., Ducreux M., Rougier P., Penault-Llorca F., and Laurent-Puig P. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66 (2006) 3992-3995
18. Charbonnier F., Raux G., Wang Q., Drouot N., Cordier F., Limacher J.M., Saurin J.C., Puisieux A., Olschwang S., and Frebourg T. Detection of exon deletions and duplications of the mismatch repair genes in hereditary nonpolyposis colorectal cancer families using multiplex polymerase chain reaction of short fluorescent fragments. Cancer Res 60 (2000) 2760-2763
19. Charbonnier F., Olschwang S., Wang Q., Boisson C., Martin C., Buisine M.P., Puisieux A., and Frebourg T. MSH2 in contrast to MLH1 and MSH6 is frequently inactivated by exonic and promoter rearrangements in hereditary nonpolyposis colorectal cancer. Cancer Res 62 (2002) 848-853
20. Di Fiore F., Charbonnier F., Martin C., Frerot S., Olschwang S., Wang Q., Boisson C., Buisine M.P., Nilbert M., Lindblom A., and Frebourg T. Screening for genomic rearrangements of the MMR genes must be included in the routine diagnosis of HNPCC. J Med Genet 41 (2004) 18-20
21. Casilli F., Di Rocco Z.C., Gad S., Tournier I., Stoppa-Lyonnet D., Frebourg T., and Tosi M. Rapid detection of novel BRCA1 rearrangements in high-risk breast-ovarian cancer families using multiplex PCR of short fluorescent fragments. Hum Mutat 20 (2002) 218-226
22. Tournier I., Paillerets B.B., Sobol H., Stoppa-Lyonnet D., Lidereau R., Barrois M., Mazoyer S., Coulet F., Hardouin A., Chompret A., Lortholary A., Chappuis P., Bourdon V., Bonadona V., Maugard C., Gilbert B., Nogues C., Frebourg T., and Tosi M. Significant contribution of germline BRCA2 rearrangements in male breast cancer families. Cancer Res 64 (2004) 8143-8147
23. Rovelet-Lecrux A., Hannequin D., Raux G., Le Meur N., Laquerriere A., Vital A., Dumanchin C., Feuillette S., Brice A., Vercelletto M., Dubas F., Frebourg T., and Campion D. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 38 (2006) 24-26
24. Forslund A., Kressner U., Lonnroth C., Andersson M., Lindmark G., and Lundholm K. P53 mutations in colorectal cancer assessed in both genomic DNA and cDNA as compared to the presence of p53 LOH. Int J Oncol 21 (2002) 409-415
25. Nakao K., Mehta K.R., Fridlyand J., Moore D.H., Jain A.N., Lafuente A., Wiencke J.W., Terdiman J.P., and Waldman F.M. High-resolution analysis of DNA copy number alterations in colorectal cancer by array-based comparative genomic hybridization. Carcinogenesis 25 (2004) 1345-1357
26. Devries S., Nyante S., Korkola J., Segraves R., Nakao K., Moore D., Bae H., Wilhelm M., Hwang S., and Waldman F. Array-based comparative genomic hybridization from formalin-fixed, paraffin-embedded breast tumors. J Mol Diagn 7 (2005) 65-71
27. Bischoff J.R., Anderson L., Zhu Y., Mossie K., Ng L., Souza B., Schryver B., Flanagan P., Clairvoyant F., Ginther C., Chan C.S., Novotny M., Slamon D.J., and Plowman G.D. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 17 (1998) 3052-3065
28. Lin J.K., Chang S.C., Yang Y.C., and Li A.F. Loss of heterozygosity and DNA aneuploidy in colorectal adenocarcinoma. Ann Surg Oncol 10 (2003) 1086-1094
29. Zauber N.P., Sabbath-Solitare M., Marotta S.P., and Bishop D.T. The adenomatous polyposis coli (APC) gene microsatellite marker D5S1385 is equally informative for loss of heterozygosity as the marker D5S346. Exp Mol Pathol 75 (2003) 144-147
30. Spirio L., Joslyn G., Nelson L., Leppert M., and White R. A CA repeat 30-70 kb downstream from the adenomatous polyposis coli (APC) gene. Nucleic Acids Res 19 (1991) 6348
31. Baselga J., and Arteaga C.L. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23 (2005) 2445-2459
32. Killian A., Sarafan-Vasseur N., Sesboue R., Le Pessot F., Blanchard F., Lamy A., Laurent M., Flaman J.M., and Frebourg T. Contribution of the BOP1 gene, located on 8q24, to colorectal tumorigenesis. Genes Chromosomes Cancer 45 (2006) 874-881